ConductScience.org, home

Paper3132385

Evaluation of in vitro antifungal activity of LY121019.

Hobbs M and 2 others. Eur J Clin Microbiol Infect Dis, 1988. Cited by 27 papers, by iCite.

Cite this record

ConductScience Library. Evaluation of in vitro antifungal activity of LY121019. Papers, record 3132385. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/3132385

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Evaluation of in vitro antifungal activity of LY121019.
PubMed
Journal
Eur J Clin Microbiol Infect Dis
PubMed
Year
1988
PubMed
Publication types
Comparative Study, Journal Article
PubMed
Citations, by iCite
27
iCite
Relative citation ratio, by iCite
1.71
iCite
Revised in PubMed
2019-08-28
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Hobbs MM
2Perfect JJ
3Durack DD

Source PubMed

Download CSV of authors

Topics8

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antifungal AgentsMajor topic
CandidaMajor topic
Candida albicansMajor topic
Peptides, CyclicMajor topic
Amphotericin B
Echinocandins
Humans
Peptides

Source PubMed

Download CSV of topics

References2

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
26389460In vitro and in vivo anti-Candida activity and toxicology of LY121019.J Antibiot (Tokyo)1984https://conductscience.org/library/papers/6389460PubMed
3984806Antimicrobial susceptibility testing of yeasts: a turbidimetric technique independent of inoculum size.Antimicrob Agents Chemother1976https://conductscience.org/library/papers/984806PubMed

Download CSV of references

Cited by13

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 27 citations.

PMIDTitleJournalYearIn PapersSource
22416196Comparative antifungal activity of cilofungin (LY121019) against Candida species, including evaluation of susceptibility testing method.Can J Infect Dis1992https://conductscience.org/library/papers/22416196PubMed
8494367Comparative efficacies of cilofungin (Ly121019) and amphotericin B against disseminated Candida albicans infection in normal and granulocytopenic mice.Antimicrob Agents Chemother1993https://conductscience.org/library/papers/8494367PubMed
8457977Compounds active against cell walls of medically important fungi.Clin Microbiol Rev1993https://conductscience.org/library/papers/8457977PubMed
2589848Treatment of experimental disseminated candidiasis with cilofungin.Antimicrob Agents Chemother1989https://conductscience.org/library/papers/2589848PubMed
2504601Fungicidal activity of cilofungin (LY121019) alone and in combination with anticapsin or other antifungal agents.Eur J Clin Microbiol Infect Dis1989https://conductscience.org/library/papers/2504601PubMed
2497014In vitro and in vivo evaluation of antifungal agents.Eur J Clin Microbiol Infect Dis1989https://conductscience.org/library/papers/2497014PubMed
2221875Comparison of cilofungin and amphotericin B for therapy of murine candidiasis.Antimicrob Agents Chemother1990https://conductscience.org/library/papers/2221875PubMed
2193617Comparative effects of cilofungin and amphotericin B on experimental murine candidiasis.Antimicrob Agents Chemother1990https://conductscience.org/library/papers/2193617PubMed
1929290Synergy between cilofungin and amphotericin B in a murine model of candidiasis.Antimicrob Agents Chemother1991https://conductscience.org/library/papers/1929290PubMed
1929288
Antifungal effects of the nonlinear pharmacokinetics of cilofungin, a 1,3-beta-glucan synthetase inhibitor, during continuous and intermittent intravenous infusions in treatment of experimental disseminated candidiasis.
Antimicrob Agents Chemother1991https://conductscience.org/library/papers/1929288PubMed
1826595W-1 solubilization and kinetics of inhibition by cilofungin of Candida albicans (1,3)-beta-D-glucan synthase.Antimicrob Agents Chemother1991https://conductscience.org/library/papers/1826595PubMed
1655435In vitro comparison of cilofungin alone and in combination with other antifungal agents against clinical isolates of Candida species.Eur J Clin Microbiol Infect Dis1991https://conductscience.org/library/papers/1655435PubMed
1379913Systemically administered antifungal agents. A review of their clinical pharmacology and therapeutic applications.Drugs1992https://conductscience.org/library/papers/1379913PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/3132385

GET https://conductscience.org/api/papers/v1/3132385/authors